Arecor Therapeutics - Non-Executive Director Board Change

Arecor Therapeutics

02/06/2025 07:00

RNS Number : 9061K

Arecor Therapeutics PLC

02 June 2025

 

Arecor Therapeutics plc

("Arecor" or the "Company")

 

NON-EXECUTIVE DIRECTOR BOARD CHANGE

 

-    Dr Alan E Smith, CBE, FRS, Ph.D., to retire as he steps down from Non-Executive Director role on Arecor's Board

 

Cambridge, UK, 2 June 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that Dr Alan Smith, who has served as a Non-Executive Director of Arecor for more than 17 years, has informed the Company that he will not seek re-election and will retire from the Board at the forthcoming annual general meeting to be held today, 2 June 2025.

 

Throughout his time at Arecor, Dr Smith has provided invaluable scientific and strategic guidance as the Company has evolved from its early stages to a clinical-stage company, underpinned by its proprietary Arestat™ technology platform.

 

Andrew Richards, Non-Executive Chair of Arecor, said: "I would like to express our sincere gratitude to Alan for his many years of dedicated service on the Board and the exceptional scientific expertise and critical insights he has brought to Arecor. His guidance to the team and the Board has been instrumental in helping Arecor advance as a company. We wish him all the best in his retirement."

 

Alan Smith, Non-Executive Director, Arecor, said: "I joined Arecor's Board because I was so impressed with the company's understanding of the science behind formulation, an area I know to be neglected at many biotech companies. I am proud of what the company has achieved and confident in its eventual success as it advances its promising pipeline of therapeutics that has the potential to significantly improve patient care."

 

-ENDS-

 

For more information, please contact:

 

Arecor Therapeutics plc
www.arecor.com
Dr Sarah Howell, Chief Executive Officer
Tel: +44 (0) 1223 426060
Email:info@arecor.com
David Ellam, Chief Financial Officer
Tel: +44 (0) 1223 426060
Email:info@arecor.com
Singer Capital Markets Advisory LLP (NOMAD and Broker)
Phil Davies, Sam Butcher
Tel: +44 (0) 20 7496 3000
ICR Healthcare
Chris Gardner, David Daley, Lindsey Neville
Tel: +44 (0) 20 3709 5700
Email:arecor@icrhealthcare.com


 

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.  For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
BOAFLFVARVILIIE